Search Results

Protagonist Therapeutics, Inc. today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.

MicroVascular Tissues, Inc., a regenerative tissue company, announces effective 12/28/2022, Anthem Blue Cross Blue Shield and Amerigroup added coverage of mVASC® Microvascular Tissue Allograft for the treatment of diabetic foot ulcers.

Senseonics Holdings, Inc. today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System.

Insightec®, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today that Anthem is the third national payor to cover MR-guided Focused Ultrasound for treating medication-refractory Essential Tremor.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Anthem, Inc. announced that it has completed its acquisition of myNEXUS, Inc., a comprehensive home-based nursing management company for payors.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).